Ocuphire Pharma Investor Day Presentation Deck
RM
69
Pre-Commercial Activities in 2022
Activities Underway to Support Capital-Efficient Nyxol RM Commercial Launch
Market
Development
Engage leading Key Opinion Leaders
and Professional Societies to establish our
commitment to refractive and retinal
disorders
Patient Journey
Establish Ocuphire as a patient-centric
company and leader in improving
everyday vision through education
to empower purchasing decisions
Physician
Targeting
Broad HCP opportunity with focus
on early adopters to capture post-market
data and patient experience
Eye Care Practitioners in U.S.
Total Ophthalmologists
Total Optometrists
Total Retina Specialists
Brand Awareness Across
Eye Care Professionals
18,000
46,000
3,000
Initiate branded and unbranded education
for ophthalmologists, optometrists and
practice professionals
Ocuphire
PHARMAView entire presentation